Shots:

• British Columbia and Health Minister Adrian Dix expand the biosimilar switching program to include Humira adalimumab and a new indication for Enbrel etanercept
• The expansion of the biosimilar switching program demonstrated the province’s continued confidence in biosimilars to manage costs and fund innovative new therapies while supporting positive patient outcomes
• BC continues to apply its biosimilar switching policy as new indications become available for marketed biosimilars- and patients taking Enbrel etanercept for the treatment of plaque psoriasis will transition to an etanercept biosimilar during the same period

  Ref: Biosimilar | Image: Twitter